CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions
The Journal of Gene Medicine · 2026-04 · 28 (4)
DOI: 10.1002/jgm.70091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Gene Medicine, online erschienen am 08.04.2026. Verfasst von Gedion Mengistu. Beteiligte Einrichtung: Department of Biotechnology, Arba Minch University, Arba Minch, Ethiopia. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Genetic Therapy, Gene Editing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
CRISPR–Cas systems have emerged as versatile platforms for targeted genome and transcriptome engineering, enabling precise manipulation of disease‐associated genetic pathways. Continued advances in CRISPR technologies including base editing, prime editing, and epigenome modulation have expanded therapeutic possibilities beyond nuclease‐mediated DNA cleavage, allowing programmable gene correction and regulation. Early clinical studies demonstrate sustained therapeutic benefit in selected monogenic disorders and highlight the feasibility of both ex vivo and in vivo editing strategies. However, clinical translation remains constrained by challenges such as off‐target activity, delivery inefficiency, immune responses to Cas proteins, editing heterogeneity, and uncertainties regarding long‐term safety. This review critically synthesizes recent advances in CRISPR–Cas systems for human disease therapy, integrating molecular innovations, delivery strategies, clinical progress, and ethical considerations. By evaluating both technological achievements and unresolved limitations, this article outlines key priorities for advancing CRISPR‐based therapeutics toward safe, effective, and equitable precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biotechnology, Arba Minch University, Arba Minch, Ethiopia.
ORCID-Profile: Gedion Mengistu
Zitieren
APA
Mengistu, G. (2026). CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions. The Journal of Gene Medicine, 28(4). https://doi.org/10.1002/jgm.70091
Vancouver
Mengistu G. CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions. The Journal of Gene Medicine. 2026;28(4). doi:10.1002/jgm.70091
BibTeX
@article{Mengistu2026,
author = {Mengistu, Gedion},
title = {CRISPR–Cas Systems in Human Disease Therapy: Advances, Clinical Applications, Limitations, and Future Directions},
journal = {The Journal of Gene Medicine},
year = {2026},
volume = {28},
number = {4},
doi = {10.1002/jgm.70091}
}
EUVIMED